Angioedema Treatment Market Report 2026

The angioedema treatment market size has grown rapidly in recent years. It will grow from $3.13 billion in 2025 to $3.59 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to emergency allergy management, hospital-based care, corticosteroid use, antihistamine availability, limited targeted drugs.

The angioedema treatment market size is expected to see rapid growth in the next few years. It will grow to $6.18 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to biologic drug development, genetic testing growth, specialty allergy clinics, patient education, preventive care focus. Major trends in the forecast period include increased use of targeted bradykinin therapies, growth of hereditary angioedema treatments, expansion of emergency treatment protocols, improved diagnostic awareness, focus on preventive therapies.

The rising incidence of rare diseases is expected to drive the growth of the angioedema treatment market in the coming years. Rare diseases are medical conditions that affect a small portion of the population, often with limited treatment options and significant health impacts. The reported occurrence of rare diseases is increasing due to advances in genetic testing and diagnostic technologies, which enable healthcare professionals to detect and accurately diagnose conditions that were previously overlooked, resulting in higher documented prevalence. Angioedema treatments are critical for rare conditions such as hereditary angioedema, providing targeted therapies that prevent and manage severe swelling episodes, thereby improving patient outcomes. For example, in November 2024, the U.S. Food and Drug Administration (FDA) reported that over 7,000 rare diseases affect more than 30 million individuals in the United States. Therefore, the rising incidence of rare diseases is fueling growth in the angioedema treatment market.

Key companies in the angioedema treatment market are focusing on innovative solutions, such as subcutaneous injections, to provide more convenient and rapid relief for patients experiencing acute hereditary angioedema (HAE) attacks. Subcutaneous injections deliver medication into the fatty tissue beneath the skin, allowing for slow and steady absorption into the bloodstream. For instance, in April 2025, CSL Limited, an Australia-based biotechnology company, launched ANDEMBRY (garadacimab), a fully human monoclonal antibody for preventing acute HAE attacks. ANDEMBRY is the first pre-filled pen designed for once-monthly subcutaneous administration, offering a convenient long-term prophylactic option. The drug works by inhibiting activated Factor XII (Factor XIIa), a key initiator in the cascade leading to angioedema, representing a significant advancement in patient-centric HAE management.

In December 2023, Ionis Pharmaceuticals Inc., a US-based biotechnology company, partnered with Otsuka Pharmaceutical Co., Ltd., a Japan-based pharmaceutical firm, to commercialize donidalorsen in Europe for the treatment of hereditary angioedema. This collaboration aims to accelerate regulatory approval and market availability of donidalorsen in Europe, leveraging Otsuka’s regional expertise to ensure access for HAE patients.

Major companies operating in the angioedema treatment market are Sanofi SA, Takeda Pharmaceutical Company Limited, Viatris Inc., Otsuka Pharmaceutical Co. Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd, Cipla Inc., Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Salix Pharmaceuticals Ltd, BioCryst Pharmaceuticals Inc., Pharming Group NV, Pharvaris Netherlands B.V, Astria Therapeutics, Intellia Therapeutics, KalVista Pharmaceuticals Ltd., ADARx Pharmaceuticals, Adverum Biotechnologies Inc.

North America was the largest region in the angioedema treatment market in 2025. The regions covered in the angioedema treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the angioedema treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the angioedema treatment market by increasing the cost of importing biologics, C1 esterase inhibitors, and injectable therapies used in hereditary and drug-induced angioedema. Injectable and biologic segments are most affected, particularly in North America and Europe, where advanced therapies are widely used. Positively, tariffs are encouraging local production of biologics and immune therapies, improving treatment availability and reducing dependency on overseas suppliers.

The angioedema treatment market research report is one of a series of new reports that provides angioedema treatment market statistics, including angioedema treatment industry global market size, regional shares, competitors with a angioedema treatment market share, detailed angioedema treatment market segments, market trends and opportunities, and any further data you may need to thrive in the angioedema treatment industry. This angioedema treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Angioedema treatment involves the medical management of swelling beneath the skin or mucous membranes, often resulting from allergic reactions, medication side effects, or genetic conditions. This swelling may be triggered by allergies, genetic factors, medications, or sometimes unknown causes, and treatment focuses on relieving symptoms, preventing airway obstruction, and reducing the frequency and severity of episodes.

The main types of angioedema treatment include allergic angioedema, drug-induced angioedema, idiopathic angioedema, and hereditary angioedema. Allergic angioedema occurs due to an allergic reaction to substances such as foods, insect bites, or medications. Treatments can be administered orally or by injection and serve a range of end-users, including hospitals, clinics, and research organizations.

The angioedema treatment market consists of revenues earned by entities providing services, such as antihistamine administration, diagnostic services, corticosteroid therapy, genetic counseling, and immunology services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.